{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T14:42:54Z","timestamp":1782225774233,"version":"3.54.5"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,2,10]],"date-time":"2009-02-10T00:00:00Z","timestamp":1234224000000},"content-version":"vor","delay-in-days":4303,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[1997,5]]},"abstract":"<jats:p>\n<jats:list list-type=\"explicit-label\">\n<jats:list-item><jats:p>Ro\u200332\u20103555 (3(<jats:bold>R<\/jats:bold>)\u2010(cyclopentylmethyl)\u2003\u2010\u20032(<jats:bold>R<\/jats:bold>)\u2003\u2010\u2003[(3,4,4\u2003\u2010\u2003trimethyl\u20102,5\u2010dioxo\u20101\u2010imidazolidinyl)methyl]\u2003\u2010\u20034\u2010oxo\u20104\u2010piperidinobutyrohydroxamic acid) is a potent, competitive inhibitor of human collagenases 1, 2 and 3 (<jats:italic>K<\/jats:italic><jats:sub>i<\/jats:sub> values of 3.0, 4.4 and 3.4\u2003n<jats:sc>M<\/jats:sc>, respectively). The compound is a selective inhibitor of collagenases over the related human matrix metalloproteinases stromelysin 1, and gelatinases A and B (<jats:italic>K<\/jats:italic><jats:sub>i<\/jats:sub> values of 527, 154 and 59\u2003n<jats:sc>M<\/jats:sc>, respectively).<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Ro 32\u20103555 inhibited interleukin\u20101\u03b1 (IL\u20101\u03b1)\u2010induced cartilage collagen degradation <jats:italic>in vitro<\/jats:italic> in bovine nasal cartilage explants (IC<jats:sub>50<\/jats:sub>=60\u2003n<jats:sc>M<\/jats:sc>).<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Ro 32\u20103555 was well absorbed in rats when administered orally. Systemic exposure was dose related, with an oral bioavailability of 26% at a dose of 25\u2003mg kg<jats:sup>\u22121<\/jats:sup>.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Ro 32\u20103555 prevented granuloma\u2010induced degradation of bovine nasal cartilage cylinders implanted subcutaneously into rats (ED<jats:sub>50<\/jats:sub>=10\u2003mg kg<jats:sup>\u22121<\/jats:sup>, twice daily, p.o.).<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Ro 32\u20103555 dosed once daily for 14 days at 50\u2003mg kg<jats:sup>\u22121<\/jats:sup>, p.o., inhibited degradation of articular cartilage in a rat monoarthritis model induced by an intra\u2010articular injection of <jats:italic>Propionibacterium<\/jats:italic> acnes.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Ro 32\u20103555 is a potential therapy for the treatment of the chronic destruction of articulating cartilage in both rheumatoid and osteoarthritis.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p>","DOI":"10.1038\/sj.bjp.0701150","type":"journal-article","created":{"date-parts":[[2006,7,21]],"date-time":"2006-07-21T14:37:20Z","timestamp":1153492640000},"page":"540-546","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Ro 32\u20103555, an orally active collagenase inhibitor, prevents cartilage breakdown <i>in vitro<\/i> and <i>in vivo<\/i>"],"prefix":"10.1111","volume":"121","author":[{"given":"E. J.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. M. K.","family":"Bottomley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bradshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Brewster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Broadhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Budd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. K.","family":"Greenham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. H.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. S.","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,2,10]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01987637"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1006\/prep.1994.1004"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/1359-6446(96)89115-X"},{"key":"e_1_2_5_5_1","first-page":"922","article-title":"Ro 32\u20130432, a selective and orally active inhibitor of protein kinase C, prevents T\u2010cell activation","volume":"268","author":"Birchall A.M.","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/10454411930040020401"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/1056-8719(93)90003-W"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06378.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"crossref","unstructured":"Borkakoti N.(1997).Zinc endoproteinases: a structural super\u2010family. Structure\u2010based drug design. InMethods and Principles in Medicinal Chemistry. ed.Gubernator K.&Boehm V.C.H. Weinheim.","DOI":"10.1002\/9783527612178.ch4"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nsb0294-106"},{"key":"e_1_2_5_11_1","doi-asserted-by":"crossref","DOI":"10.1042\/bj3230483","article-title":"Inhibition of bovine nasal cartilage breakdown by selective inhibitors of matrix metalloproteinases","author":"Bottomley K.","year":"1997","journal-title":"Biochem. J."},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780340902"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-199505000-00003"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0076-6879(95)48027-7"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02546393"},{"key":"e_1_2_5_16_1","doi-asserted-by":"crossref","first-page":"16766","DOI":"10.1016\/S0021-9258(19)89457-7","article-title":"Molecular cloning and expression of collagenase 3 \u2010 a novel human matrix metalloproteinase produced by breast carcinomas","volume":"269","author":"Freije J.M.P.","year":"1994","journal-title":"J. Biol. Chem."},{"key":"e_1_2_5_17_1","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.4049\/jimmunol.136.7.2492","article-title":"Recombinant interleukin\u20101\u03b1: Purification and biological characterisation","volume":"136","author":"Gubler U.","year":"1986","journal-title":"J. Immunol."},{"key":"e_1_2_5_18_1","first-page":"41","volume-title":"Research Monographs in Cell and Tissue Physiology.","author":"Hardingham T.E.","year":"1988"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(88)90025-2"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/14756368709030352"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(80)90295-X"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(92)80300-6"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780170316"},{"key":"e_1_2_5_24_1","first-page":"179","volume-title":"Research Monographs in Cell and Tissue Physiology","author":"Krane S.M.","year":"1988"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(89)90042-9"},{"issue":"1","key":"e_1_2_5_26_1","first-page":"494","article-title":"Efficacy of Ro 31\u20139790, an orally active collagenase inhibitor, in animal models of arthritis","volume":"20","author":"Lewis E.J.","year":"1993","journal-title":"Rev. Esp. Rheumatol."},{"key":"e_1_2_5_27_1","first-page":"188P","article-title":"Efficacy of the cartilage protective agent (Ro 32\u2013355) in in vitro and in vivo models of cartilage degradation","volume":"119","author":"Lewis E.J.","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00366a031"},{"key":"e_1_2_5_29_1","first-page":"237","article-title":"Potent collagenase inhibitors prevent interleukin\u20101\u2010induced cartilage degradation in vitro","volume":"13","author":"Nixon J.S.","year":"1991","journal-title":"Int. J. Tiss. Reac."},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.22.8749"},{"key":"e_1_2_5_31_1","doi-asserted-by":"crossref","first-page":"22342","DOI":"10.1016\/S0021-9258(18)45711-0","article-title":"Rat collagenase: cloning, amino acid sequence comparison, and parathyroid hormone regulation in osteoblastic cells","volume":"265","author":"Quinn C.O.","year":"1990","journal-title":"J. Biol. Chem."},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00541335"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.7.15.8262328"},{"key":"e_1_2_5_34_1","first-page":"187P","article-title":"Pharmacokinetics and metabolism of a new cartilage protective agent","volume":"119","author":"Sutton B.","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01966491"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2780179"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1995.9929"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.5.8.1850705"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0701150","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0701150","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0701150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T08:31:46Z","timestamp":1698395506000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0701150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,5]]}},"alternative-id":["10.1038\/sj.bjp.0701150"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0701150","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,5]]},"assertion":[{"value":"2009-02-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}